Evaluate COVID-19 EventAnalyzer
A weekly global roundup of key COVID-19 events driving company valuations.
|Key COVID-19 Market Movers up to 1 April 2020|
|Company||Market Cap Change (US $mln)||Market Cap (US $mln)||Calculated Share Price Impact (%)||EventAnalyzer Note|
|Johnson & Johnson||+25,968||339,589||+8%||
COVID-19 Vaccine Development
30 Mar: Selects lead COVID-19 vaccine candidate, expands BARDA co-funding to $1bn; Expects to initiate human trial SEP 2020 latest and anticipates first batch of vaccine for emergency use early 2021. Will establish new US vaccine manufacturing capabilities.
COVID-19 Drug Development: Remdesivir (nucleotide inhibitor)
25 Mar: Shares fall after the company requests FDA to remove orphan drug status for remdesivir, following public disapproval of the decision.
18 Mar: Shares continue to rise. Analyst from Piper Sandler suggests remdesivir could receive regulatory approval 'very soon' off early data.
26 Feb: Company initiates two PIII studies of its antiviral drug, Remdesivir for treatment of COVID-19.
23 Jan: Company reports that it is evaluating its experimental Ebola drug, remdesivir, for the potential treatment of COVID-19.
COVID-19 Drug Development: Actemra (anti-IL-6 MAb)
04 Mar: China’s National Health Commission recommend use of company's anti-inflammation drug, Actemra for COVID-19 patients with serious lung damage and high IL-6 levels.
COVID-19 Diagnostics Development
16 Mar: Company announces shipping of first 400,000 Cobas SARS-CoV-2 diagnostic tests across US, following granting of FDA Emergency Use Authorisation (EUA).
13 Mar: FDA grants emergency authorization for the company's COVID-19 test, which provides results in three and a half hours.
COVID-19 Drug Development: Kevzara (anti-IL-6 MAb)
30 Mar: Sanofi/Regeneron's Kevzara treats first patient in phase II/III trial.
16 Mar: Initiation of global clinical program for severe COVID-19 infection. PII/PIII trial already initiated in the US and will enroll patients immediately.
10 Mar [post market]: The Wall Street Journal reports plans to evaluate arthritis drug, Kevzara, for the treatment of symptoms of COVID-19.
COVID-19 Vaccine Development
18 Feb: Company to collaborate with BARDA to develop an advanced pre-clinical SARS vaccine for COVID-19 virus.
COVID-19 Vaccine Development: (BNT162)
19 Mar: Shares fall back after rising 38% after string two day gain.
16-18 Mar: Shares rise after announcement of collaboration with Pfizer for WW ex-China and Fosun Pharma for China to develop the company's mRNA vaccine candiate, BNT162, for the prevention of COVID-19 infections on 17 Mar. Plan to initiate clinical trials in late April 2020.
COVID-19 Vaccine Development: mRNA-1273 (mRNA vaccine)
16 Mar: Company announces the first participant dosed in the phase I trial of its mRNA-1273 vaccine for COVID-19.
11 Mar: Reuters reports that the company plans to initiate a trial for COVID-19 in collaboration with the National Institutes of Health for 45 people in Seattle this month.
25 Feb: Company to initiate phase I study of its mRNA-1273 for COVID-19 by the end of April.
07 Feb: The USA NIAID (NIH) director states during a White House news conference that the development of the company's COVID-19 vaccine is proceeding well, with hopes to to initiate phase I trials within 2.5 months.
COVID-19 Drug Development
12 Mar: Company signs a letter of intent with Biogen to develop human monoclonal antibodies for COVID-19 treatment.
COVID-19 Vaccine Development.
11 Mar: Company announces collaboration with the NIH and the National Institute of Allergy and Infectious Diseases (NIAID) to develop antibodies against COVID-19.
25-26 Feb: Company announces collaboration with WuXi Biologics for the global development of antibodies to treat COVID-19.
24 Jan: Shares continue to rise after company announces they are working on a multi-pronged strategy for tackling COVID-19, on 23 Jan.
COVID-19 Drug Development: TAK-888 (plasma-derived drug)
05 Mar: Shares rise a day after company announces initiation of development of a plasma-derived drug, TAK-888 for COVID-19, on 4 Mar. TAK-888, is a serum therapy made from the antibodies of recovered COVID-19 patients.
COVID-19 Diagnostics Development: Leronlimab (anti-CCR 5 MAb)
30 Mar: Shares rise following news leronlimab used in 3 additional severe COVID-19 cases, bringing the total to 10 treated, with 2 intubated patients able to leave the ICU with reduced pulmonary inflammation.
27 Mar: Files FDA-suggested modifications to IND for PII trial. Positive results have been seen amongst seven COVID-19 patients in New York treated.
29 Jan: Exploring use in COVID-19.
COVID-19 Drug Development: Kaletra (lopinavir; ritonavir)
06 Feb: Shares rise after a broker report discloses antiretroviral drug Kaletra has become a sought-after antidote for COVID-19.
COVID-19 Profit Risk
31 Mar: To reduce COVID-19 exposure risk, temporarily pauses enrolment and screening of trials wherever safety and data integrity could become an issue and decides to suspend all in-person meetings and interactions with healthcare company and professionals in US.
COVID-19 Profit Risk
14 Feb: Company’s Q4’19 revenue misses analyst expectations with collaboration revenue of $414m, a decrease of 36.2% compared to last year. Moreover, company assumes an unfavourable impact on the 2020 financial outlook due to the COVID-19 outbreak in China.
|Source: Evaluate, April 2020.|